ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Centre of the pharmaverse
An all-encompassing digital era has opened unique opportunities for industry to engage with patients meaningfully. Read more in PharmaTimes' Jan. 2019 article.
How to accelerate drug development for patients with rare diseases
ICON’s Marie McCarthy, Pavel Lebesle, and Matthew McCarty discuss how to accelerate drug development for patients with rare diseases in this Pharmafile article.
How Value-Based Healthcare Affects Medical Device Development
Read this MPO Magazine article written by ICON expert Vicki Anastasi on how value-based healthcare (VBHC) models are expected to transform the health sector.
Pharma R&D Business Models Under Pressure To Improve Efficiency
Read this article to learn how to improve the efficiency of trial designs & procedures throughout the drug development process.
Ten Developments to Watch Out For in Life Sciences
Discover the top digital & tech developments in the life science industry, including mHealth, AI, robotic process automation, and more.
Optimizing Study Design in Real-World Evidence Generation
Discover the importance of specialist epidemiology knowledge, due to their specialised focus on pharmacoepidemiological study design, to ensure robust and reliable downstream study findings.
A Look at Cost Challenges of Precision Medicine & Rare Disease
The cost challenges presented by precision medicine in rare disease, and the strategies that can be employed to overcome them.
Connecting With The Patient
E.B. McLindon explains how ICON is taking a different approach with its Integrated Site Network in this Scrip 100 media article.
An "Icon" in Clinical Research
An article discussing ICON's unmatched global reach & expertise in oncology & work with Pfizer.
ACT NOW – Cancer Trials At The Leading Edge
A thought leadership article by Martin Lachs, Olivier Saulin and Chris Learn on how CROs can best support increasing demand for ACT clinical trials.